Skip Navigation


NDT Advance Access originally published online on June 13, 2007
Nephrology Dialysis Transplantation 2007 22(11):3202-3207; doi:10.1093/ndt/gfm347
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/11/3202    most recent
gfm347v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Westerberg, P.-A.
Right arrow Articles by Larsson, T. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Westerberg, P.-A.
Right arrow Articles by Larsson, T. E.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org



Regulation of fibroblast growth factor-23 in chronic kidney disease

Per-Anton Westerberg1, Torbjörn Linde1, Björn Wikström1, Östen Ljunggren1, Mats Stridsberg2 and Tobias E. Larsson1

1Department of Medical Sciences and2Department of Clinical Chemistry, Uppsala University Hospital, Uppsala, Sweden

Correspondence and offprint requests to: Tobias E. Larsson, Department of Medical Sciences, Uppsala University Hospital, Ing. 70, 3 tr., UAS, 75185 Uppsala, Sweden. Email: Tobias.Larsson{at}medsci.uu.se



  Abstract

Background. Fibroblast growth factor-23 (FGF23) is a circulating factor that regulates the renal reabsorption of inorganic phosphate (Pi) and is increased in chronic kidney disease (CKD). The aim of the current investigation was to study the regulation of FGF23 in CKD subjects with various degree of renal function. As such, we analysed the relationship between FGF23, Pi, calcium, parathyriod hormone (PTH), 25(OH) vitamin D3(25(OH)D3), 1,25(OH)2 vitamin D3(1,25(OH)2D3) and estimated glomerular filtration rate (eGFR).

Methods. Intact FGF23 and other biochemical variables were analysed in 72 consecutive adult out-patients with various stages of CKD (eGFR ranging from 4–96 ml/min.) Association studies were performed using linear univariate and multivariate analysis.

Results. FGF23 was significantly elevated at CKD stage 4 (266 ± 315 pg/ml, P < 0.001) and 5 (702 ± 489 pg/ml, P < 0.001) compared with CKD 1–2 (46 ± 43 pg/ml). In CKD 4–5 an independent association between log FGF23 and Pi (P < 0.001), 25(OH)D3 (P < 0.05) as well as eGFR (P < 0.01) was observed. In contrast, in CKD 1–3 log PTH (P < 0.05) was the only independent predictor of log FGF23 in multivariate analysis. In CKD 1–5, Pi (P < 0.00001) and log PTH (P < 0.01) were explanatory variables for log FGF23 in multivariate analysis.

Conclusions: We conclude that serum FGF23 increases in CKD 4–5, in parallel with the emerging hyperphosphataemia. Serum Pi is the most important predictor of FGF23 when GFR is less than 30 ml/min. In contrast, our data suggest that Pi may not be an important determinant of FGF23 in normophosphataemic CKD subjects. Finally, the association between FGF23 and PTH in CKD may suggest a co-regulation that remains to be further elucidated.

Keywords: chronic kidney disease; fibroblast growth factor-23(FGF23); hyperphosphataemia; parathyroid hormone; phosphate

Received for publication: 7. 2.07
Accepted in revised form: 7. 5.07


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
G. Jean, J.-C. Terrat, T. Vanel, J.-M. Hurot, C. Lorriaux, B. Mayor, and C. Chazot
High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients
Nephrol. Dial. Transplant., September 1, 2009; 24(9): 2792 - 2796.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
J. Danziger
The bone-renal axis in early chronic kidney disease: an emerging paradigm
Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2733 - 2737.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
T. Isakova, O. Gutierrez, A. Shah, L. Castaldo, J. Holmes, H. Lee, and M. Wolf
Postprandial Mineral Metabolism and Secondary Hyperparathyroidism in Early CKD
J. Am. Soc. Nephrol., March 1, 2008; 19(3): 615 - 623.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
R. Marsell, E. Grundberg, T. Krajisnik, H. Mallmin, M. Karlsson, D. Mellstrom, E. Orwoll, C. Ohlsson, K. B Jonsson, O. Ljunggren, et al.
Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men
Eur. J. Endocrinol., January 1, 2008; 158(1): 125 - 129.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.